A Scoping Review of Persistent Symptoms after COVID Infection at Different Follow-Up Periods

Simple item page
dc.contributor.authorSreelakshmi, PRen_US
dc.contributor.authorTandale, BVen_US
dc.contributor.authorJadhav, AVen_US
dc.contributor.authorVaidya, RRen_US
dc.contributor.authorWalimbe, AMen_US
dc.contributor.authorJadhav, S.en_US
dc.date.accessioned2023-08-19T04:56:11Z
dc.date.available2023-08-19T04:56:11Z
dc.date.issued2022-06
dc.description.abstractThe clinical entity termed as long COVID has gained importance in the recent past. As this phenomenon is still evolving, it is important to document the magnitude of the syndrome during different time periods. This scoping review attempts to synthesize evidence generated from longitudinal studies which have follow‑up periods beyond 3 months, up to 12 months. The review also documents the reported prevalence of long COVID for the different regions of the World Health Organization. Longitudinal studies published till March 2022 were systematically searched on PubMed, Google Scholar, and medRxiv. Among the identified 594 studies, 48 were included in this review. Data from selected studies were synthesized. The overall pooled prevalence of long COVID was 49% (40%–58%). The pooled estimates after 3 months, 4–6 months, 7–9 months, and 10–12 months were 44% (32%–57%), 50% (43%–57%), 49% (37%–62%), and 54% (46%–62%), respectively. Eastern Mediterranean Region (EMR) had the highest pooled prevalence of 63% (34%–92%] and the South East Asian Region (SEAR) had the least pooled estimate of 15% (10%–21%). The study brings out the high prevalence of long COVID even after 12 months of follow‑up. It also shows the regional differences in the reported prevalence of the syndrome. This review highlights the need for well‑planned follow‑up studies, especially in developing nations to understand the magnitude and the pattern of long COVID‑related symptoms as they emerge.en_US
dc.identifier.affiliationsScientist‑Den_US
dc.identifier.affiliationsScientist F and Group Leaderen_US
dc.identifier.affiliationsScientist Een_US
dc.identifier.affiliationsInternship Trainee, Epidemiology Groupen_US
dc.identifier.affiliationsStatistician, Bio‑Informatics Group, ICMR‑National Institute of Virology, Pune, Maharashtra, Indiaen_US
dc.identifier.citationSreelakshmi PR, Tandale BV, Jadhav AV, Vaidya RR, Walimbe AM, Jadhav S.. A Scoping Review of Persistent Symptoms after COVID Infection at Different Follow-Up Periods. Indian Journal of Public Health. 2023 Jun; 67(2): 292-300en_US
dc.identifier.issn0019-557X
dc.identifier.issn2229-7693
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223927
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber2en_US
dc.relation.volume67en_US
dc.source.urihttps://doi.org/10.4103/ijph.ijph_1178_22en_US
dc.subjectLong COVIDen_US
dc.subjectpersistent symptomsen_US
dc.subjectpostacute coronavirus (COVID‑19) syndromeen_US
dc.subjectpost COVID syndromeen_US
dc.subjectscoping reviewen_US
dc.subjectsequelaeen_US
dc.titleA Scoping Review of Persistent Symptoms after COVID Infection at Different Follow-Up Periodsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJPH2023v67n2p292.pdf
Size:
3.63 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Public Health